Walpar Nutritions (WALPAR) Stock Overview
Manufactures and trades pharmaceutical, nutraceutical, herbal, and ayurvedic commodities in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
WALPAR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Walpar Nutritions Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹22.35 |
| 52 Week High | ₹53.30 |
| 52 Week Low | ₹22.35 |
| Beta | -0.60 |
| 1 Month Change | -38.77% |
| 3 Month Change | n/a |
| 1 Year Change | -56.81% |
| 3 Year Change | -44.26% |
| 5 Year Change | n/a |
| Change since IPO | -21.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| WALPAR | IN Personal Products | IN Market | |
|---|---|---|---|
| 7D | -21.6% | 2.0% | -2.1% |
| 1Y | -56.8% | -9.5% | -4.6% |
Return vs Industry: WALPAR underperformed the Indian Personal Products industry which returned -10% over the past year.
Return vs Market: WALPAR underperformed the Indian Market which returned -5.1% over the past year.
Price Volatility
| WALPAR volatility | |
|---|---|
| WALPAR Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: WALPAR's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: Insufficient data to determine WALPAR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Kalpesh Ladhawala | www.walparnutritions.com |
Walpar Nutritions Limited manufactures and trades pharmaceutical, nutraceutical, herbal, and ayurvedic commodities in India. The company offers G-Flora, a probiotic blend for gut health and immunity; Inosia-F, an inositol supplement; Inovam Plus, a multivitamin; Ironica-CR, controlled-release iron supplement; Myobest, muscle support formula; Ovality, ovarian health support; Ovanyx-F, a female reproductive health supplement; Ovacon-F, women's fertility support; PCOS Care Forte, a PCOS support; Procive-F, female fertility enhancement supplement; Procive-M, a male fertility enhancement supplement; Refitil-M, a male reproductive health support; Cranvilin, a cranberry extract; Drostility, a fertility support; and FTM Plus and Mancare Forte, a male health support formula. It also provides FTW Plus, a women's health support formula; Joint-CR, a joint care supplement; Mecowal, a vitamin B12 supplement for neurological health; Megorich omega-3 fatty acids for heart and brain health; Ni-1000, niacin supplement for cardiovascular support; Ortin-5, an orthopedic support; Ova-Wom, a women's wellness formula; PCOS Care, support for PCOS management; PDF, digestive health support with probiotics and enzymes; Piyo, natural antioxidant support; ProPlus multivitamin; Seagut, marine-based digestive health supplement; Semen Care, specialized male reproductive health formula;Sleep Sound, natural sleep support; Spinac, a spinal health support; Trivita, triple-action vitamin complex; and Wal-D3, a vitamin D3 for bone and immune health.
Walpar Nutritions Limited Fundamentals Summary
| WALPAR fundamental statistics | |
|---|---|
| Market cap | ₹209.88m |
| Earnings (TTM) | ₹23.31m |
| Revenue (TTM) | ₹757.46m |
Is WALPAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WALPAR income statement (TTM) | |
|---|---|
| Revenue | ₹757.46m |
| Cost of Revenue | ₹589.45m |
| Gross Profit | ₹168.00m |
| Other Expenses | ₹144.69m |
| Earnings | ₹23.31m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.48 |
| Gross Margin | 22.18% |
| Net Profit Margin | 3.08% |
| Debt/Equity Ratio | 41.1% |
How did WALPAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 08:37 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Walpar Nutritions Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.